These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 27217043)

  • 21. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation.
    Manzoor BS; Lee TA; Sharp LK; Walton SM; Galanter WL; Nutescu EA
    Pharmacotherapy; 2017 Oct; 37(10):1221-1230. PubMed ID: 28730619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Renal Function on Dosing of Non-Vitamin K Antagonist Direct Oral Anticoagulants Among Patients With Nonvalvular Atrial Fibrillation.
    Shrestha S; Baser O; Kwong WJ
    Ann Pharmacother; 2018 Feb; 52(2):147-153. PubMed ID: 28856898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation.
    Alalwan AA; Voils SA; Hartzema AG
    Am J Health Syst Pharm; 2017 Aug; 74(16):1237-1244. PubMed ID: 28652320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of Oral Anticoagulant Dosing and Adherence to Therapy Among Patients With Nonvalvular Atrial Fibrillation.
    Rymer JA; Chiswell K; Young L; Chiu A; Liu L; Webb L; Carlisle M; Friedman D; Wang TY
    JAMA Netw Open; 2023 Jun; 6(6):e2317156. PubMed ID: 37285155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
    Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced Doses of Direct Oral Anticoagulants in Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation.
    Deguchi I; Takao M
    J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):354-359. PubMed ID: 30401611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras.
    Brown JD; Shewale AR; Dherange P; Talbert JC
    Drugs Aging; 2016 Jun; 33(6):427-36. PubMed ID: 27154397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation.
    Manzano-Fernández S; Andreu-Cayuelas JM; Marín F; Orenes-Piñero E; Gallego P; Valdés M; Vicente V; Lip GY; Roldán V
    Rev Esp Cardiol (Engl Ed); 2015 Jun; 68(6):497-504. PubMed ID: 25457087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uptake of Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in a Single Clinical Commissioning Group in England Without Restrictions to Their Use.
    Medlinskiene K; Fay M; Petty D
    Clin Drug Investig; 2019 Apr; 39(4):401-405. PubMed ID: 30805790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The acceptability of a direct oral anticoagulant monitoring regimen among patients with atrial fibrillation: a pilot study.
    Mourad AP; Aslani P; D'Souza M; Brieger D
    Int J Clin Pharm; 2019 Jun; 41(3):682-686. PubMed ID: 31016680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Thromboembolic prophylaxis 2011: is warfarin on the wane?].
    Di Pasquale G; Riva L
    G Ital Cardiol (Rome); 2011 Sep; 12(9):556-65. PubMed ID: 21892216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of Recurrent Ischemic Stroke with Unintended Low-Dose Oral Anticoagulant Therapy and Optimal Timing of Review.
    Shinoda N; Mori M; Tamura S; Korosue K; Kose S; Kohmura E
    J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1546-1551. PubMed ID: 29395644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic.
    ; Curtis HJ; MacKenna B; Walker AJ; Croker R; Mehrkar A; Morton C; Bacon S; Hickman G; Inglesby P; Bates C; Evans D; Ward T; Cockburn J; Davy S; Bhaskaran K; Schultze A; Rentsch CT; Williamson E; Hulme W; Tomlinson L; Mathur R; Drysdale H; Eggo RM; Wong AY; Forbes H; Parry J; Hester F; Harper S; Douglas I; Smeeth L; Goldacre B
    Open Heart; 2021 Nov; 8(2):. PubMed ID: 34785588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
    Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
    Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes Associated With Resuming Direct Oral Anticoagulant Therapy Following Admission for a Gastrointestinal Bleed.
    Valanejad SM; Davis KA; Nisly SA
    Ann Pharmacother; 2020 Oct; 54(10):975-980. PubMed ID: 32141301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.